NeuroPace Q1 RNS rev $21.7M (+19.5%); raises FY26 rev guidance to $99-101M

NeuroPace Inc

2026-Q1 EPS reported -$0.20 vs consensus -$0.23 ▲ beat (+14.7%)

RNS System revenue $21.7M (+19.5% YoY); total revenue $22.1M including $0.1M DIXI Medical.
GAAP net loss $6.7M; Adjusted EBITDA loss ex DIXI improved to $3.3M from $4.1M YoY.
Cash $54.8M vs $61.2M prior quarter; long-term debt $59M.
FY2026 revenue guidance raised to $99-101M (from $98-100M), representing 21-23% RNS growth.
Expects IGE indication expansion contribution after potential NAUTILUS PMA-S approval mid-2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NeuroPace Inc reported first quarter ended March 31, 2026 results: revenue Total revenue of $22.1 million, net income ($6.7) million. Guidance raised.

Period: first quarter ended March 31, 2026
Revenue: Total revenue of $22.1 million
Net income: ($6.7) million
Guidance: raised
Result: reported results

Exact text from the filing

forth by specific reference in such filing. --- EX-99 (EX-99.1) --- NeuroPace Reports First Quarter 2026 Financial Results and Raises 2026 Revenue Guidance Total revenue of $22.1 million Raises full year 2026 guidance to $99 million to $101 million, up from $98 million to $100 million previously Assumes 21% to 23% growth in core RNS ® revenue from existing

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

NeuroPace Inc filing history →

Source: SEC EDGAR

accession 0001528287-26-000019

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.